Diagnosis and Discussion -- Case 1068
Introduction - Targeting METex14 NSCLC - Text Module - MET Inhibition in NSCLC - Oncology - Clinical Care Options
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration | Nature Medicine
Targeting MET in Lung Cancer: Will Expectations Finally Be MET? - Abstract - Europe PMC
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - ScienceDirect
Novel MET Exon 14 Skipping Treatment-Naïve Lung Adenocarcinoma Presented Primary Resistance to Crizotinib - Journal of Thoracic Oncology
The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable - ScienceDirect
![MET Exon 14 Skipping Mutations in Non-small Cell Lung Cancer]. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/67fdcd54f931874b6e6ffa4ffca44de1124ea7f0/5-Figure1-1.png "MET Exon 14 Skipping Mutations in Non-small Cell Lung Cancer]. | Semantic Scholar")
MET Exon 14 Skipping Mutations in Non-small Cell Lung Cancer]. | Semantic Scholar
Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer | Journal of Hematology & Oncology | Full Text
Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation - Lung Cancer
Characterization of MET exon 14 alteration and association with clinical outcomes of crizotinib in Chinese lung cancers - Lung Cancer
Lung cancer with MET exon 14 skipping mutation | LCTT
Identification of a Novel MET Exon 14 Skipping Variant in Lung Adenocarcinoma Sensitive to Crizotinib Treatment - Journal of Thoracic Oncology
METex14 in non-small lung cancers. (a) schematic diagram of genomic... | Download Scientific Diagram
Identification of tumor-specific, intronic mutations in Met leading to... | Download Scientific Diagram
Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro - ScienceDirect
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - ScienceDirect
Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping - Journal of Thoracic Oncology
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration | Nature Medicine
An improved assay for detection of theranostic gene translocations and MET exon 14 skipping in thoracic oncology | Laboratory Investigation
Genomic and clinical characteristics of MET exon14 alterations in a large cohort of Chinese cancer patients revealed distinct features and a novel resistance mechanism for crizotinib
A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations - Santarpia - Translational Lung Cancer Research
A) Kaplan–Meier survival curves for relapse free according to MET exon... | Download Scientific Diagram
Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer | NEJM
